FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017109215> ?p ?o ?g. }

• W2017109215 endingPage "15" @default.
• W2017109215 startingPage "9" @default.
• W2017109215 abstract "In patients with chronic liver diseases, thrombocytopenia is a common manifestation which interferes with antiviral therapy for hepatitis C virus (HCV), and with hepatocellular carcinoma (HCC) treatment. While thrombopoietin-receptor agonist is expected to improve thrombocytopenia for patients with chronic liver diseases in 2-3 weeks, there is still a lack of fundamental data about short-term variations in the natural course of platelet count in cirrhotic patients, and the impact of thrombocytopenia on antiviral therapy for HCV-infected patients and patients being treated for HCC. The aims of this study are to investigate sequential changes in platelet count and the impact of thrombocytopenia on antiviral therapy and HCC treatment in patients with chronic liver diseases. A total of 726 chronic liver disease patients were enrolled in this study. Changes of platelet count were examined during a 4-week follow-up. Risk of discontinuation or reduction of peginterferon dosage was evaluated in HCV patients with moderate thrombocytopenia (5-10x10(4)/microL). Risk of platelet transfusion or splenectomy was evaluated in HCC patients with severe thrombocytopenia (<5x10(4)/microL). No significant changes of platelet count were observed in cirrhotic patients with thrombocytopenia during a 4-week follow-up. The rate of discontinuation or reduction in dosage of peginterferon was 85.2% (23/27) in patients with moderate thrombocytopenia. Risk of discontinuation or reduction of peginterferon dosage was 3.4-times higher in HCV patients with thrombocytopenia than in those without thrombocytopenia. In HCC patients with severe thrombocytopenia, the frequency of platelet transfusion or splenectomy during HCC treatment was 57.9% (22/38). Risk of platelet transfusion or splenectomy in HCC patients with thrombocytopenia was 57.9-times higher than in those without thrombocytopenia. In conclusion, we demonstrated no significant variation in the short-term natural course of platelet count in cirrhotic patients. In chronic liver disease patients with moderate and severe thrombocytopenia, about 85% of patients treated with peginterferon, and 60% of patients receiving HCC treatments suffered from thrombocytopenia-related limitations, respectively." @default.
• W2017109215 created "2016-06-24" @default.
• W2017109215 creator A5003720698 @default.
• W2017109215 creator A5019384052 @default.
• W2017109215 creator A5019463160 @default.
• W2017109215 creator A5033954465 @default.
• W2017109215 creator A5047338429 @default.
• W2017109215 creator A5047725445 @default.
• W2017109215 creator A5065417614 @default.
• W2017109215 creator A5074132164 @default.
• W2017109215 creator A5084794851 @default.
• W2017109215 date "2009-01-01" @default.
• W2017109215 modified "2023-10-16" @default.
• W2017109215 title "Thrombocytopenia, an Important Interfering Factor of Antiviral Therapy and Hepatocellular Carcinoma Treatment for Chronic Liver Diseases" @default.
• W2017109215 cites W1967118686 @default.
• W2017109215 cites W1967711533 @default.
• W2017109215 cites W1968478756 @default.
• W2017109215 cites W1978339383 @default.
• W2017109215 cites W1981031886 @default.
• W2017109215 cites W2004979253 @default.
• W2017109215 cites W2005804181 @default.
• W2017109215 cites W2009378591 @default.
• W2017109215 cites W2009575651 @default.
• W2017109215 cites W2011707824 @default.
• W2017109215 cites W2013946336 @default.
• W2017109215 cites W2024258010 @default.
• W2017109215 cites W2032640357 @default.
• W2017109215 cites W2037100061 @default.
• W2017109215 cites W2041220983 @default.
• W2017109215 cites W2051505813 @default.
• W2017109215 cites W2056173679 @default.
• W2017109215 cites W2063291570 @default.
• W2017109215 cites W2071246402 @default.
• W2017109215 cites W2078887584 @default.
• W2017109215 cites W2086647861 @default.
• W2017109215 cites W2088319815 @default.
• W2017109215 cites W2088740001 @default.
• W2017109215 cites W2109713965 @default.
• W2017109215 cites W2124086403 @default.
• W2017109215 cites W2144837804 @default.
• W2017109215 cites W2170075593 @default.
• W2017109215 cites W2593890559 @default.
• W2017109215 cites W4244215862 @default.
• W2017109215 doi "https://doi.org/10.2739/kurumemedj.56.9" @default.
• W2017109215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20103996" @default.
• W2017109215 hasPublicationYear "2009" @default.
• W2017109215 type Work @default.
• W2017109215 sameAs 2017109215 @default.
• W2017109215 citedByCount "8" @default.
• W2017109215 countsByYear W20171092152012 @default.
• W2017109215 countsByYear W20171092152013 @default.
• W2017109215 countsByYear W20171092152014 @default.
• W2017109215 countsByYear W20171092152018 @default.
• W2017109215 countsByYear W20171092152019 @default.
• W2017109215 countsByYear W20171092152020 @default.
• W2017109215 crossrefType "journal-article" @default.
• W2017109215 hasAuthorship W2017109215A5003720698 @default.
• W2017109215 hasAuthorship W2017109215A5019384052 @default.
• W2017109215 hasAuthorship W2017109215A5019463160 @default.
• W2017109215 hasAuthorship W2017109215A5033954465 @default.
• W2017109215 hasAuthorship W2017109215A5047338429 @default.
• W2017109215 hasAuthorship W2017109215A5047725445 @default.
• W2017109215 hasAuthorship W2017109215A5065417614 @default.
• W2017109215 hasAuthorship W2017109215A5074132164 @default.
• W2017109215 hasAuthorship W2017109215A5084794851 @default.
• W2017109215 hasBestOaLocation W20171092151 @default.
• W2017109215 hasConcept C109159458 @default.
• W2017109215 hasConcept C126322002 @default.
• W2017109215 hasConcept C203014093 @default.
• W2017109215 hasConcept C2522874641 @default.
• W2017109215 hasConcept C2776309230 @default.
• W2017109215 hasConcept C2776408679 @default.
• W2017109215 hasConcept C2776455275 @default.
• W2017109215 hasConcept C2776689292 @default.
• W2017109215 hasConcept C2777214474 @default.
• W2017109215 hasConcept C2777863708 @default.
• W2017109215 hasConcept C2778019345 @default.
• W2017109215 hasConcept C2778713057 @default.
• W2017109215 hasConcept C2778715236 @default.
• W2017109215 hasConcept C2779102576 @default.
• W2017109215 hasConcept C2780588981 @default.
• W2017109215 hasConcept C2780931953 @default.
• W2017109215 hasConcept C28328180 @default.
• W2017109215 hasConcept C2993327898 @default.
• W2017109215 hasConcept C54355233 @default.
• W2017109215 hasConcept C71924100 @default.
• W2017109215 hasConcept C86803240 @default.
• W2017109215 hasConcept C89560881 @default.
• W2017109215 hasConcept C90924648 @default.
• W2017109215 hasConceptScore W2017109215C109159458 @default.
• W2017109215 hasConceptScore W2017109215C126322002 @default.
• W2017109215 hasConceptScore W2017109215C203014093 @default.
• W2017109215 hasConceptScore W2017109215C2522874641 @default.
• W2017109215 hasConceptScore W2017109215C2776309230 @default.
• W2017109215 hasConceptScore W2017109215C2776408679 @default.
• W2017109215 hasConceptScore W2017109215C2776455275 @default.
• W2017109215 hasConceptScore W2017109215C2776689292 @default.
• W2017109215 hasConceptScore W2017109215C2777214474 @default.

• next